After hospital discharge, about 40% of Medicare beneficiaries receive post-acute care (PAC) services, such as home health care (HHC), skilled nursing, or inpatient rehabilitation. But do they get the right care at the right time?
Five percent of Medicaid enrollees account for nearly 50% of Medicaid spending, making this high-cost group a promising target for care management programs.
Over the past two decades, opioid overdose mortality nationwide more than doubled from 21,000 deaths in 2000 to 47,000 deaths in 2017. In a new study of Medicaid enrollees, a team of LDI fellows sheds light on the degree to which new or repeated overdoses may be driving this trend—with significant implications for overdose reduction.
As the opioid epidemic rages on, clinicians are looking towards safer medication alternatives for patients with acute and chronic pain. Skeletal Muscle Relaxers (SMRs) are a common opioid substitute for patients with musculoskeletal conditions. Although their use has grown at a rate similar to that of opioids, little is known about their safety and efficacy in treating long-term, chronic pain, particularly for older patients and patients with simultaneous opioid use.
Low back pain is a major cause of disability among adults and a top reason patients are prescribed opioids. However, a recent study in the Journal of the American Board of Family Medicine finds that patients with new low back pain are receiving opioids less frequently, though prescribing rates remain uneven across the country.
A voluntary UnitedHealthcare program to reduce oncologists’ financial incentives to prescribe brand-name anticancer drugs failed to increase prescribing of generic equivalents.
On September 13 and 14, the University of Pennsylvania Law School, Penn LDI, and Princeton University's Center for Health and Wellbeing will host the Sixth Annual Health Insurance Exchange Conference. This nonpartisan, off-the-record workshop brings together senior state policymakers and researchers studying health care markets to discuss the latest research on the exchanges and current challenges.
Pharmaceutical company payments can significantly influence physician prescribing behavior, according to a recent National Bureau of Economics Research (NBER) Working Paper by LDI Senior Fellows Matthew Grennan, Ashley Swanson, and colleagues.
Financial conflicts of interest between the drug and device industry and physicians have long been recognized, but the frequency and scope of such conflicts between industry and patient advocacy organizations (PAOs) are less understood.
The adequacy of “narrow network” plans offered on the Affordable Care Act (ACA) Marketplaces continues to be a concern in the wake of exclusions of some high-cost providers and the incidence of “surprise medical bills” even in facilities that are in-network.